LV12585B - LONG-TERM CONTINUOUS ACTIVITY (PROLONGED ACTIVITY) PREPARATION FOR HEAD ANTAGONIST, ITS ACQUISITION AND APPLICATION - Google Patents

LONG-TERM CONTINUOUS ACTIVITY (PROLONGED ACTIVITY) PREPARATION FOR HEAD ANTAGONIST, ITS ACQUISITION AND APPLICATION Download PDF

Info

Publication number
LV12585B
LV12585B LVP-00-110A LV000110A LV12585B LV 12585 B LV12585 B LV 12585B LV 000110 A LV000110 A LV 000110A LV 12585 B LV12585 B LV 12585B
Authority
LV
Latvia
Prior art keywords
compound
group
sustained
acid
angiotensin
Prior art date
Application number
LVP-00-110A
Other languages
English (en)
Latvian (lv)
Other versions
LV12585A (en
Inventor
Yasutaka Igari
Akira Saikawa
Yoshiyuki Inada
Shigeru Kamei
Original Assignee
Takeda Chemical Industries, Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd filed Critical Takeda Chemical Industries, Ltd
Publication of LV12585A publication Critical patent/LV12585A/xx
Publication of LV12585B publication Critical patent/LV12585B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
LVP-00-110A 1998-03-04 2000-08-16 LONG-TERM CONTINUOUS ACTIVITY (PROLONGED ACTIVITY) PREPARATION FOR HEAD ANTAGONIST, ITS ACQUISITION AND APPLICATION LV12585B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP5236698 1998-03-04
PCT/JP1999/001011 WO1999044590A1 (en) 1998-03-04 1999-03-03 Sustained-release preparation for aii antagonist, production and use thereof

Publications (2)

Publication Number Publication Date
LV12585A LV12585A (en) 2000-12-20
LV12585B true LV12585B (en) 2001-03-20

Family

ID=12912818

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-00-110A LV12585B (en) 1998-03-04 2000-08-16 LONG-TERM CONTINUOUS ACTIVITY (PROLONGED ACTIVITY) PREPARATION FOR HEAD ANTAGONIST, ITS ACQUISITION AND APPLICATION

Country Status (21)

Country Link
US (2) US6589547B1 (es)
EP (1) EP1058541B1 (es)
KR (1) KR20010086245A (es)
CN (1) CN1291888A (es)
AT (1) ATE258430T1 (es)
AU (1) AU2745199A (es)
BR (1) BR9908474A (es)
CA (1) CA2318446C (es)
DE (1) DE69914460T2 (es)
EE (1) EE200000499A (es)
ES (1) ES2214013T3 (es)
HU (1) HUP0101439A3 (es)
ID (1) ID25640A (es)
IL (1) IL137979A0 (es)
LT (1) LT4800B (es)
LV (1) LV12585B (es)
NO (1) NO20004350L (es)
PL (1) PL342684A1 (es)
SK (1) SK11902000A3 (es)
WO (1) WO1999044590A1 (es)
ZA (1) ZA991706B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL137979A0 (en) * 1998-03-04 2001-10-31 Takeda Chemical Industries Ltd Production, release preparation for aii antagonist-sustained and use thereof
WO2000066161A1 (fr) 1999-04-28 2000-11-09 Takeda Chemical Industries, Ltd. Preventifs / remedes / inhibiteurs de progression pour retinopathie simplex ou retinopathie preproliferante
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
WO2001060362A1 (en) * 2000-02-18 2001-08-23 Takeda Chemical Industries, Ltd. TNF-α INHIBITORS
AU2001232348A1 (en) * 2000-02-21 2001-08-27 Takeda Chemical Industries Ltd. Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same
WO2002015935A1 (fr) * 2000-08-25 2002-02-28 Takeda Chemical Industries, Ltd. Agents de reduction du fibrinogene
US20040102502A1 (en) * 2000-10-25 2004-05-27 Toshifumi Watanabe Preventing/remedies for portal hypertension
WO2002074340A1 (fr) * 2001-03-16 2002-09-26 Takeda Chemical Industries, Ltd. Procede de fabrication d'une preparation a liberation continue
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
BRPI0105509B8 (pt) * 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
WO2003041739A1 (en) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Anticaner agents
AU2002349673A1 (en) * 2001-12-03 2003-06-17 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
KR101092279B1 (ko) * 2002-12-27 2011-12-13 다케다 야쿠힌 고교 가부시키가이샤 체중 증가 억제제
US20050038093A1 (en) * 2003-05-02 2005-02-17 Boehringer Ingelheim International Gmbh Treating diabetic retinopathy with angiotensin II receptor blockers
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
CN1795198B (zh) * 2003-05-29 2011-08-17 杰伊·W·佩特格尤 对神经精神疾病进行医学成像所用的甘油磷酸胆碱及其衍生物
WO2005097109A1 (en) * 2004-04-01 2005-10-20 Daniel Batlle Methods for achieving a protective ace2 expression level
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
AU2005290394A1 (en) * 2004-10-07 2006-04-13 Takeda Pharmaceutical Company Limited Agent for prophylaxis or treatment of metabolic syndrome
US8022086B2 (en) * 2004-10-29 2011-09-20 Kowa Co., Ltd. Therapeutic agent for glomerular disease
EP1850835A1 (fr) * 2005-02-21 2007-11-07 Flamel Technologies Forme pharmaceutique orale de losartan
GEP20115138B (en) * 2005-03-30 2011-01-10 Takeda Pharmaceuticals Co Benzimidazole derivative and use as angiotensin ii antagonist
KR20080039510A (ko) * 2005-08-22 2008-05-07 알렘빅 리미티드 발사르탄 제조 방법
ZA200901075B (en) * 2006-08-10 2010-05-26 Takeda Pharmaceutical Pharmaceutical composition
PE20081364A1 (es) * 2006-09-04 2008-12-04 Novartis Ag Composicion farmaceutica que comprende valsartan
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
CL2007003658A1 (es) 2006-12-18 2008-05-09 Takeda Pharmaceutical Composicion de liberacion sostenida que comprende un peptido; procedimiento para preparar dicha composicion; agente profilactico o terapeutico para cancer de prostata, hiperplasia prostatica, endometriosis, fibroide uterino, fibroma uterino, pubertad
CN101011393B (zh) * 2007-02-16 2010-10-06 广州柏赛罗药业有限公司 厄贝沙坦胃内滞留型缓释药物组合物
AU2008235790B2 (en) * 2007-03-28 2013-06-06 Takeda Pharmaceutical Company Limited Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
WO2009134057A2 (ko) * 2008-04-29 2009-11-05 한올제약주식회사 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
CA2761576C (en) 2009-05-20 2017-08-22 Boehringer Ingelheim Vetmedica Gmbh Oral suspension comprising telmisartan
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2751907A (en) * 1953-09-18 1956-06-26 Bishop & Co Platinum Works J Pellet injector
JPS5671073A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
JPS5671074A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
IE802177L (en) 1980-10-21 1981-05-12 Takeda Chemical Industries Ltd Imidazol-5-ylacetic acid derivatives
JPS58157768A (ja) 1982-03-16 1983-09-19 Takeda Chem Ind Ltd ４−クロロ−２−フエニルイミダゾ−ル−５−酢酸誘導体
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4820843A (en) 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4898732A (en) * 1988-05-04 1990-02-06 The Clinipad Corporation Inhibiting of tumor growth with an antagonist of the renin-angioten-sin system
DE3928177A1 (de) 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
DE69010076T2 (de) * 1989-05-25 1994-12-08 Takeda Chemical Industries Ltd Transdermales therapeutisches Mittel.
CA2018443A1 (en) 1989-06-14 1990-12-14 Joseph A. Finkelstein Imidazolyl-alkenoic acids
RU2099330C1 (ru) 1989-06-30 1997-12-20 Е.И.Дюпон Де Немур Энд Компани Замещенные имидазолы или их фармацевтически приемлемые соли и фармацевтическая композиция
CA2020073A1 (en) 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
EP0407342A3 (en) 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
EP0409332A3 (en) 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
EP0411507B1 (en) 1989-08-02 1994-10-26 Takeda Chemical Industries, Ltd. Pyrazole derivatives, their production and use
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
EP0434038A1 (en) 1989-12-22 1991-06-26 Takeda Chemical Industries, Ltd. Fused imidazole derivatives, their production and use
DE69129998T2 (de) 1990-02-15 1998-12-24 Takeda Chemical Industries, Ltd., Osaka Pyrimidindionderivate, deren Herstellung und Verwendung
CA2036618C (en) * 1990-02-22 2002-10-29 Akira Morimoto Fused thiophene derivatives, their production and use
IE912956A1 (en) * 1990-09-10 1992-03-11 Abbott Lab Angiotensin ii receptor antagonists
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
TW274551B (es) 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
CZ36394A3 (en) * 1991-08-19 1994-07-13 Du Pont Substituted imidazilonone derivatives and pharmaceutical preparations based thereon
TW284688B (es) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
GB2272899A (en) * 1992-11-30 1994-06-01 Du Pont Merck Pharma Angiotensin-11 receptor blocking cycloalkylbenzylimidazoles
EP0603712B1 (en) 1992-12-22 2001-08-16 Takeda Chemical Industries, Ltd. Heterocyclic compounds having angiotensin II antagonistic activity and use thereof
US5288720A (en) * 1993-04-23 1994-02-22 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
KR101222904B1 (ko) * 1993-07-19 2013-01-17 안지오테크 파마슈티칼즈, 인코포레이티드 항맥관형성 조성물, 당해 조성물로 피복된 스텐트 및 당해 스텐트의 제조방법
JPH0789849A (ja) 1993-09-20 1995-04-04 Fujisawa Pharmaceut Co Ltd 徐放性製剤
CA2224381A1 (en) * 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
DK0889880T3 (da) 1996-03-29 2003-09-01 Smithkline Beecham Corp Eprosartan-dihydrat og fremgangsmåde til fremstilling deraf samt formulering
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6201002B1 (en) * 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
US5958884A (en) * 1997-04-11 1999-09-28 The Brigham And Women's Hospital, Inc. Compositions and methods for treating erectile dysfunction
US6306826B1 (en) * 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
IL137979A0 (en) * 1998-03-04 2001-10-31 Takeda Chemical Industries Ltd Production, release preparation for aii antagonist-sustained and use thereof

Also Published As

Publication number Publication date
BR9908474A (pt) 2000-12-05
LT4800B (lt) 2001-06-25
SK11902000A3 (sk) 2001-02-12
NO20004350L (no) 2000-10-03
EP1058541B1 (en) 2004-01-28
ZA991706B (en) 2000-10-03
CA2318446A1 (en) 1999-09-10
US7294344B2 (en) 2007-11-13
EE200000499A (et) 2002-02-15
EP1058541A1 (en) 2000-12-13
US6589547B1 (en) 2003-07-08
ATE258430T1 (de) 2004-02-15
CA2318446C (en) 2008-09-23
HUP0101439A3 (en) 2002-09-30
US20030198676A1 (en) 2003-10-23
CN1291888A (zh) 2001-04-18
AU2745199A (en) 1999-09-20
NO20004350D0 (no) 2000-09-01
DE69914460T2 (de) 2004-10-28
PL342684A1 (en) 2001-07-02
WO1999044590A1 (en) 1999-09-10
DE69914460D1 (de) 2004-03-04
KR20010086245A (ko) 2001-09-10
LV12585A (en) 2000-12-20
IL137979A0 (en) 2001-10-31
HUP0101439A2 (hu) 2001-10-28
ES2214013T3 (es) 2004-09-01
LT2000082A (en) 2001-03-26
ID25640A (id) 2000-10-19

Similar Documents

Publication Publication Date Title
EP1058541B1 (en) Sustained-release preparation for aii antagonist, production and use thereof
EP1346722B1 (en) Method for producing preparation containing bioactive substance
EP0442671B1 (en) Prolonged release microcapsules
JP2670680B2 (ja) 生理活性物質含有ポリ乳酸系微小球およびその製造法
CA2456034A1 (en) Sustained-release medicines
US20040121008A1 (en) Process for producing sustained release preparation
AU2004264885B2 (en) Aripiprazole and haloperidol pamoate salts
JP4409135B2 (ja) 生理活性物質含有製剤の製造法
JP2020506232A (ja) ゴナドトロピン放出ホルモン（ＧｎＲＨ）拮抗薬の長期放出のための組成物および方法
JP2526589B2 (ja) ペプチド含有マイクロカプセルおよびその製造法
US20030068374A1 (en) Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same
CA2776472A1 (en) Microparticle compositions and methods for treating age-related macular degeneration
CA2407472A1 (en) Sustained release compositions
JP2004525167A (ja) 動脈性高血圧症、他の心血管疾患、及びその合併症を治療するためのアンギオテンシンｉｉａｔ１受容体拮抗薬製剤の調製
JP3765338B2 (ja) 注射用徐放性製剤の製造法
EP1312379A1 (en) Fibrinogen lowering agents
JP2008505057A (ja) 徐放性組成物、その製造法および用途
EP1329218A1 (en) Preventives/remedies for portal hypertension
JPH11315034A (ja) アンギオテンシンｉｉ拮抗作用を有する化合物の徐放性製剤、その製造法および用途
JP4900984B2 (ja) 徐放性製剤の製造法
JP2003212758A (ja) 徐放性製剤の製造法
MXPA00008171A (es) Preparacion de antagonista aii de liberacion prolongada, produccion y uso de los mismos
CZ20003164A3 (cs) Prostředek s prodlouženým uvolňováním pro antagonistů angiotensinu II, jeho příprava a použití
JP2001316296A (ja) 水に難溶性の生理活性化合物の徐放性製剤、その製造法および用途
JP2002201128A (ja) 門脈圧亢進症予防・治療剤